Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Serial Radionuclide Assessment Of Doxorubicin Cardiotoxicity In Cancer Patients With Abnormal Baseline Resting Left Ventricular Performance

B.William Choi, H. Berger, P. E. Schwartz, J. Alexander, F. J. T. Wackers, A. Gottschalk, B. Zaret
Published 1983 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Abstract While previous studies have demonstrated that sequential radionuclide angiocardiography allows identification of patients at risk for development of congestive heart failure and prediction of the appropriate time for safe discontinuation of doxorubicin, these studies were based predominantly on patients with normal baseline left ventricular performance. This study addresses the use of doxorubicin in patients with abnormal left ventricular ejection fraction ( p = NS). Only in the 12 patients who received ≥350 mg/m 2 cumulative dose was there a small but significant fall in left ventricular ejection fraction (48 ± 4 vs 43 ± 8%, p
This paper references
10.1016/0002-9343(81)90574-X
Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart.
F. Brosius (1981)
10.1016/0002-9149(68)90143-4
The heart in acute leukemia. A study of 420 autopsy cases.
W. Roberts (1968)
Radionuclide ejection fraction in doxorubicin cardiotoxicity.
G. Morgan (1981)
10.7326/0003-4819-80-2-249
Adriamycin. A new anticancer drug with significant clinical activity.
R. Blum (1974)
Radiation-induced heart disease. Clinical and experimental aspects.
J. Stewart (1971)
10.1097/00005792-196705000-00003
HEART DISEASE FOLLOWING RADIATION
K. Cohn (1967)
Myocardial imaging with a radioiodinated norepinephrine storage analog.
D. M. Wieland (1981)
10.1016/S0001-2998(79)80014-8
First-pass radionuclide assessment of right and left ventricular performance in patients with cardiac and pulmonary disease.
H. Berger (1979)
10.1002/1097-0142(19800901)46:5<1109::AID-CNCR2820460506>3.0.CO;2-B
Anthracycline cardiotoxicity: Clinical and pathologic outcomes assessed by radionuclide ejection fraction
J. Ritchie (1980)
10.1016/0146-2806(80)90011-0
The management of congestive heart failure.
P. Gazes (1980)
10.1002/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO;2-M
Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage schedule
R. Benjamin (1974)
10.1016/S0046-8177(75)80078-5
Pathology of high dose intermittent cyclophosphamide therapy.
R. E. Slavin (1975)
10.1016/0002-9149(78)90011-5
Variability in sequential measures of left ventricular performance assessed with radionuclide angiocardiography.
R. Marshall (1978)
10.1056/NEJM198011133032001
Effect of age on the response of the left ventricular ejection fraction to exercise.
S. Port (1980)
10.1056/NEJM198110083051504
Nuclear cardiology (second of two parts).
Berger Hj (1981)
10.1056/NEJM197902083000603
Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
J. Alexander (1979)
10.1016/0002-9149(80)91010-3
Identification of subclinical cardiac abnormality 5–15 Yrs. After therapeutic mediastinal irradiation
J. Gottdiener (1980)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
10.1056/NEJM197805252982108
Case 20-1978
R. Desanctis (1978)
10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2
A clinicopathologic analysis of adriamycin cardiotoxicity
E. Lefrak (1973)
10.1016/0002-9343(81)90168-6
Pericardial disease in patients with cancer. The differentiation of malignant from idiopathic and radiation-induced pericarditis.
M. Posner (1981)
10.1002/1097-0142(197704)39:4<1397::AID-CNCR2820390407>3.0.CO;2-U
Adriamycin cardiomyopathy—risk factors
R. A. Minow (1977)
10.7326/0003-4819-94-4-430
Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography.
J. Gottdiener (1981)
10.1016/0146-2806(80)90005-5
Cardiac disease in patients who have malignancies.
M. M. Applefeld (1980)
10.1161/01.CIR.56.5.820
Assessment of Cardiac Performance with Quantitative Radionuclide Angiocardiography: Sequential Left Ventricular Ejection Fraction, Normalized Left Ventricular Ejection Rate, and Regional Wall Motion
R. Marshall (1977)
10.1016/0360-3016(78)90053-6
The etiologies of coronary artery disease in cancer patients.
G. Kopelson (1978)
10.1056/NEJM198110013051405
Nuclear cardiology (first of two parts).
Berger Hj (1981)
10.7326/0003-4819-96-2-133
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
10.7326/0003-4819-88-2-168
Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.
M. Bristow (1978)



This paper is referenced by
10.1007/s12350-015-0194-4
Can serial changes of diastolic dysfunction signal incremental risk of chemotherapy-induced heart failure missed by the timing of declining LV ejection fraction?
R. Schwartz (2015)
10.1016/0045-9380(93)90019-9
Late effects of childhood cancer therapy.
L. Meister (1993)
10.1016/0146-2806(94)90006-X
Radionuclide assessment of ventricular function.
L. Johnson (1994)
10.1007/s12350-013-9707-1
Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively
R. Schwartz (2013)
radioisotópica em pacientes submetidos à quimioterapia com antraciclinas na infância e adolescência
São Paulo. (2015)
10.1007/978-3-0348-7772-5_77
Follow-Up of Cardiac Toxicity of Anthracycline Chemotherapy with Equilibrium Radionuclide Angiography
F. Patrois (1997)
10.1007/BF00834534
Nuclear medicine at the crossroads
H. Strauss (2004)
Platelet aggregation inhibitors in prevention and treatment of coronary thrombosis.
M. Gomes (2003)
10.1007/s10741-016-9564-5
Current views on anthracycline cardiotoxicity
D. Mele (2016)
10.5555/URI:PII:009377549290207H
The cardiotoxicity of chemotherapeutic drugs.
A. Allen (1992)
10.1007/BF02577349
Quantitative radionuclide angiocardiography
J. Grégoire (2007)
10.1097/00000421-199704000-00005
The role of radionuclide angiocardiography in the treatment of patients receiving doxorubicin-based chemotherapy: a reassessment.
R. Dreicer (1997)
10.1016/J.AMJCARD.2005.02.001
Barry Lewis Zaret, MD: a conversation with the editor. Interview by William Clifford Roberts.
B. Zaret (2005)
10.1093/ehjci/jeu192
Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
J. Plana (2014)
10.1016/0735-1097(92)90497-B
Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.
S. Klewer (1992)
10.1007/s11912-016-0532-y
Echocardiography and Alternative Cardiac Imaging Strategies for Long-Term Cardiotoxicity Surveillance of Cancer Survivors Treated with Chemotherapy and/or Radiation Exposure
Vinisha Garg (2016)
10.1016/j.mayocp.2014.05.013
Evaluation and management of patients with heart disease and cancer: cardio-oncology.
J. Herrmann (2014)
Imagerie des complications cardiaques des traitements anticancéreux (médecine nucléaire, IRM)
A. Manrique (2009)
Late-onset cardiotoxicity of chemotherapy and radiotherapy.
B. Dietz (2003)
10.1007/s12350-019-01671-6
Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods
Aaron Soufer (2019)
10.1016/0002-8703(83)90651-8
Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.
J. Mckillop (1983)
10.1007/978-94-009-7630-6_31
Cardiac Monitoring of Patients Receiving Anthracyclines
M. Bristow (1982)
10.1007/s12350-015-0274-5
Imaging and chemotherapy cardiotoxicity: A long-playing story still seeking precision and improved outcomes/management data
W. V. Van Decker (2015)
10.1016/j.jaccao.2020.01.005
Repeated Remote Ischemic Conditioning Reduces Doxorubicin-Induced Cardiotoxicity
Q. He (2020)
10.15420/ecr.2017:17:2
Cardio-oncology: A Focus on Cardiotoxicity.
A. Koutsoukis (2018)
10.1007/BF02574768
Assessment of left ventricular diastolic function in patients receiving anthracycline therapy
S. Parmentier (2007)
10.1016/0002-8703(86)90112-2
Lower incidence of doxorubicin-induced cardiomyopathy by once-a-week low-dose administration.
R. J. Anders (1986)
10.1016/0002-9149(86)90284-5
Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.
S. Palmeri (1986)
10.1016/J.NUCLCARD.2004.11.004
Measurement of ventricular function with scintigraphic techniques: Part 1—Imaging hardware, radiopharmaceuticals, and first-pass radionuclide angiography
K. Williams (2005)
10.1007/s002800051005
In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy
P. Nony (2000)
10.1007/s12350-016-0538-8
The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy
R. Russell (2016)
10.1016/S0031-3955(02)00032-9
Late effects of childhood cancer therapy.
D. Friedman (2002)
See more
Semantic Scholar Logo Some data provided by SemanticScholar